Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide.
Undervalued with solid track record.
Share Price & News
How has Celgene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CG3 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CG3 exceeded the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: CG3 exceeded the German Market which returned 17.1% over the past year.
Price Volatility Vs. Market
How volatile is Celgene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Celgene undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CG3 (€97.75) is trading below our estimate of fair value (€154.12)
Significantly Below Fair Value: CG3 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CG3 is good value based on its PE Ratio (13x) compared to the Biotechs industry average (35.3x).
PE vs Market: CG3 is good value based on its PE Ratio (13x) compared to the German market (20.6x).
Price to Earnings Growth Ratio
PEG Ratio: CG3 is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: CG3 is overvalued based on its PB Ratio (6.4x) compared to the DE Biotechs industry average (3.4x).
How is Celgene forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CG3's forecast earnings growth (15.6% per year) is above the savings rate (0.2%).
Earnings vs Market: CG3's earnings (15.6% per year) are forecast to grow faster than the German market (13.2% per year).
High Growth Earnings: CG3's earnings are forecast to grow, but not significantly.
Revenue vs Market: CG3's revenue (8.6% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: CG3's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CG3's Return on Equity is forecast to be very high in 3 years time (41.9%).
How has Celgene performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CG3 has high quality earnings.
Growing Profit Margin: CG3's current net profit margins (34.6%) are higher than last year (19.6%).
Past Earnings Growth Analysis
Earnings Trend: CG3's earnings have grown significantly by 23.7% per year over the past 5 years.
Accelerating Growth: CG3's earnings growth over the past year (103.3%) exceeds its 5-year average (23.7% per year).
Earnings vs Industry: CG3 earnings growth over the past year (103.3%) exceeded the Biotechs industry 5.4%.
Return on Equity
High ROE: Whilst CG3's Return on Equity (48.65%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
How is Celgene's financial position?
Financial Position Analysis
Short Term Liabilities: CG3's short term assets ($14.5B) exceed its short term liabilities ($5.0B).
Long Term Liabilities: CG3's short term assets ($14.5B) do not cover its long term liabilities ($24.3B).
Debt to Equity History and Analysis
Debt Level: CG3's debt to equity ratio (163.7%) is considered high.
Reducing Debt: CG3's debt to equity ratio has increased from 118.8% to 163.7% over the past 5 years.
Debt Coverage: CG3's debt is well covered by operating cash flow (41.2%).
Interest Coverage: CG3's interest payments on its debt are well covered by EBIT (13.2x coverage).
Inventory Level: CG3 has a low level of unsold assets or inventory.
Debt Coverage by Assets: CG3's debt is not covered by short term assets (assets are 0.7x debt).
What is Celgene's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CG3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CG3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CG3's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CG3's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CG3's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Alles (60yo)
Mr. Mark J. Alles has been the Chief Executive Officer of Celgene Corporation since March 1, 2016 and its chairman of the board since February 5, 2018. Mr. Alles served as the President and Chief Operating ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD16.22M) is above average for companies of similar size in the German market ($USD4.52M).
Compensation vs Earnings: Mark's compensation has increased by more than 20% in the past year.
|Chairman & CEO||3.7yrs||US$16.22m||0.032% $22.2m|
|Executive VP & Chief Corporate Strategy Officer||5.3yrs||US$6.24m||0.0076% $5.3m|
|President of Global Clinical Development||1yrs||US$6.05m||0.0010% $702.4k|
|President of Global Inflammation & Immunology||2.6yrs||US$4.24m||0.00074% $514.6k|
|Executive VP & CFO||1.3yrs||no data||0.0020% $1.4m|
|Senior VP and Chief Digital & Information Officer||1.3yrs||no data||no data|
|Corporate Vice President of Investor Relations||0yrs||no data||no data|
|Executive VP & General Counsel||1.3yrs||no data||0.0010% $695.5k|
|Senior VP & Chief Compliance Officer||1yrs||no data||no data|
|VP of Corporate Communications and Senior Director of Public Relation & IR||16.7yrs||no data||no data|
Experienced Management: CG3's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Chairman & CEO||3.7yrs||US$16.22m||0.032% $22.2m|
|Independent Director||4.6yrs||US$535.75k||0.00059% $410.3k|
|Independent Lead Director||12.4yrs||US$590.01k||0.020% $14.0m|
|Independent Director||12.3yrs||US$560.01k||0.0096% $6.7m|
|Independent Director||9.9yrs||US$535.75k||0.0056% $3.9m|
|Independent Director||1.8yrs||US$822.31k||0.00078% $542.5k|
|Independent Director||7.8yrs||US$537.51k||0.0019% $1.3m|
|Independent Director||12.8yrs||US$565.01k||0.0061% $4.3m|
|Independent Director||8.8yrs||US$530.01k||0.0028% $1.9m|
|Independent Director||4.1yrs||US$537.51k||0.00034% $236.5k|
Experienced Board: CG3's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CG3 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Celgene Corporation's company bio, employee growth, exchange listings and data sources
- Name: Celgene Corporation
- Ticker: CG3
- Exchange: DB
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$76.958b
- Listing Market Cap: US$69.547b
- Shares outstanding: 711.71m
- Website: https://www.celgene.com
Number of Employees
- Celgene Corporation
- 86 Morris Avenue
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CELG||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 1987|
|CG3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 1987|
|CG3||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jul 1987|
|CELG *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 1987|
|CELG||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Jul 1987|
|0QYA||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 1987|
|CELG||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jul 1987|
|CLGN34||BOVESPA (Bolsa de Valores de Sao Paulo)||EACH BDR REPR 1 COM USD0.01||BR||BRL||Nov 2015|
|CELG||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 5 REP 1 COM USD0.01||AR||ARS||Apr 2019|
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. The company also has strategic collaboration with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules that modulate RNA splicing. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/11/20 20:45|
|End of Day Share Price||2019/11/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.